News
Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification has been secured to deliver CNJ-016® [Vaccinia Immune Globulin Intravenous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback